Merck: There’s more to our business than Keytruda. Really

Merck: There’s more to our business than Keytruda. Really

STAT Plus: Merck: There’s more to us than Keytruda. Really

By MATTHEW HERPER

MEL EVANS/AP

In the third quarter of 2018, sales of the drug reached $1.9 billion — 18 percent of Merck’s revenue. But the company says its portfolio remains diverse.

READ MORE